Explore our VHH resources
Sign up for our VHH Newsletter and stay in the loop with the latest news, research papers, blog articles.
Accelerating VHH-enabled Antibody-Oligonucleotide Conjugates Discovery
AOC targeting ligands need to combine specificity, internalisation, developability and conjugation compatibility. Explore how synthetic VHH discovery platforms can address these requirements earlier in development.
Why VHHs Are Attractive Targeting Ligands for Antibody-Oligonucleotide Conjugates
Effective AOCs depend on more than the oligonucleotide payload. This article examines the targeting and intracellular delivery process and why VHH antibodies offer useful properties for AOC design. Read more
How Are Antibody-Oligonucleotide Conjugates Being Applied?
AOCs are being explored across muscle, rare disease, CNS and immuno-oncology programmes. This article reviews representative programmes and compares AOCs with LNPs, viral vectors, GalNAc conjugates and local delivery. Read more
Why Antibody–Oligonucleotide Conjugates Are Gaining Momentum
AOCs combine antibody-based targeting with therapeutic oligonucleotides to support receptor-mediated delivery and intracellular activity. This overview explains how the modality works, its core components and how it differs from mAbs and ADCs. Read more
Lipid Nanoparticles for Drug Delivery: Precision Targeting Beyond the Liver — and the Role of VHHs
Lipid nanoparticles are central to nucleic acid delivery but remain constrained by liver tropism and limited cell specificity. This article examines how VHH antibodies enable receptor-mediated targeting, supporting extrahepatic delivery while maintaining manufacturability and scalability. Read more
VHH and the blood–brain barrier challenge
The blood–brain barrier remains a critical bottleneck in CNS drug delivery, excluding nearly all biologics. VHH antibodies offer a practical route forward, combining small size, stability, and engineering flexibility to enable receptor-mediated transport into the brain. This article examines transport mechanisms, emerging applications, and how synthetic VHH libraries support the development of brain-penetrant biologics. Read more
Explore the science behind our antibody discovery platforms
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy. Download Extending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable. DOWNLOADAdvantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note. DOWNLOADOptimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. DOWNLOADIsogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. DOWNLOADAnti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery… DOWNLOAD